Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer

International Journal of Cancer

Volumn 87, Issue 3, 2000, Pages 405-411

  Silvestrini, Rosella ^a   Luisi, Antonella ^a   Zambetti, Milvia ^a   Cipriani, Sonia ^a   Valagussa, Pinuccia ^a   Bonadonna, Gianni ^a   Daidone, Maria Grazia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CHRONOPHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034256089     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000801)87:3<405::aid-ijc15>3.0.co;2-%23     Document Type: Article

References (26)

1. AKAIKE, H., Information theory and an extension of the maximum likelihood principle. In:B.N. Patrov and F. Csaki (eds.), Proceedings of the Second International Symposium on Information Theory, Akademia Kiado, Budapest (1973).
2. AMADORI, D., and 14 OTHERS, Prospective use of tumor proliferate activity for adjuvant therapy in node-negative breast cancer patients. Cell Prolif., 30, 467 (1997).
3. BONADONNA, G., ZAMBETTI, M., VALAGUSSA, P., Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. J. amer. med. Assoc., 273, 542-547 (1995).
4. DAIDONE, M.G., SILVESTRINI, R., LUISI, A., MASTORE, M., BENINI, E., VENERONI, S., BRAMBILLA, C., FERRARI, L., GRECO, M., ANDREOLA, S., and VERONESI, U., Changes in biological markers after primary chemotherapy for breast cancers. Int. J. Cancer, 61, 301-305 (1995).
5. DURRLEMAN, S., and SIMON, R., Flexible regression models with cubic splines. Stat. Med., 8, 551-561 (1989).
6. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339, 1-15, 71-85 (1992).
7. EARLY BREAST CANCER TRIALISTS' COOPERATIVE GROUP, Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet, 352, 930-942 (1998).
8. ELLEDGE, R.M., GRAY, R., MANSOUR, E., YU, Y., CLARK, G.M., RAVDIN, P., OSBORNE, C.K., GILCHRIST, K., DAVIDSON, N.E., ROBERT, N., TORMEY, D.C., and ALLRED, D.C., Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. nat. Cancer Inst., 87, 1254-1256 (1995).
9. ELLEDGE, R.M., and 12 OTHERS, Bc1-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. J. clin. Oncol., 15, 1916-1922 (1997).
10. GASPARINI, G., and 12 OTHERS, Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. nat. Cancer Inst., 89, 139-147 (1997).
11. GEE, J.M.W., ROBERTSON, J.F., ELLIS, I.O., WILLSHER, P., MCCLELLAND, R.A., HOYLE, H.B., KYME, S.R., FINLAY, P., BLAMEY, R.W., and NICHOLSON, R.I., Immunocytochemical localisation of bc1-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer, 59, 619-628 (1994).
12. KRAJEWSKI, S., BLOMQVIST, C. FRANSSILA, K., KRAJEWSKA, M., WASENIUS, V.-M., NISKANEN, E., NORDLING, S., and REED, J.C., Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55, 4471-4478 (1995).
13. cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol. Pharmacol., 49, 832-841 (1996).
14. NICHOLSON, R.I., BOUZUBAR, N., WALKER, K.J., MCCLELLAND, R., DIXON, A.R., ROBERTSON, J.F., ELLIS, I.O., BLAMEY, R.W., Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Europ. J. Cancer, 27, 908-913 (1991).
15. O'REILLY, S.M., CAMPLEJOHN, R.S., MILLIS, R.R., RUBENS, R.D., and RICHARDS, M.A., Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Europ. J. Cancer, 26, 1035-1038 (1990).
16. PARADISO, A., and 12 OTHERS, Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer. Drugs, 45, 68-74 (1993).
17. REMVIKOS, Y., JOUVE, M, BEUZEBOC, P., VIEHL, P., MAGDELENAT, H., and POUILLART, P., Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Europ. J. Cancer, 29A, 1843-1848 (1993).
18. SILVESTRINI, R., BENINI, E., VENERONI, S., DAIDONE, M.G., TOMASIC, G., SQUICCIARINI, P., and SALVADORI, B., p53 and bc1-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. clin. Oncol., 14, 1604-1610 (1996a).
19. SILVESTRINI, R., DAIDONE, M.G., BENINI, E., FARANDA, A., TOMASIC, G., BORACCHI, P., SALVADORI, B., and VERONESI, U., Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin. Cancer Res., 2, 2007-2013 (1996b).
20. 3H-thymidine labelling index. Int. J. Cancer, 74, 122-127 (1997a).
21. SILVESTRINI, R., VENERONI, S., BENINI, E., DAIDONE, M.G., LUISI, A., LEUTNER, M., MAUCIONE, A., KENDA, R., ZUCALI, R., and VERONESI, U., Expression of p53, GST-π and bc1-2 and benefit from adjuvant radiotherapy in breast cancer. J. nat. Cancer Inst., 89, 639-645 (1997b).
22. SJOGREN, S., INGANAS, M., LINDGREN, A., HOLMBERG, L., and BERGH, J., Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. clin. Oncol., 16, 462-469 (1998).
23. STAL, O., SKOOG, L., RUTQVIST, L.E., CARSTENSEN, J.M., WINGREN, S., SULLIVAN, S., ANDERSSON, A.C., DUFMATS, M., and NORDENSKJOLD, B., S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Brit. J. Cancer, 70, 1258-1262 (1994).
24. THOR, A.D., BERRY, D.A., BUDMAN, D.R., MUSS, H.B., KUTE, T., HENDERSON, I.C., BARCOS, M., CIRRINCIONE, C., EDGERTON, S., ALLRED, C., NORTON, L., and LIU, E.T., ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. nat. Cancer Inst., 90, 1346-1360 (1998).
25. VERONESI, U., and 13 OTHERS, Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Europ. J. Cancer, 26, 668-670 (1990).
26. ZAMBETTI, M., BONADONNA, G., VALAGUSSA, P., and BIGNAMI, P., Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results. Ann. Oncol., 7, 481-485 (1996).